Wayne S Kendal1. 1. Division of Radiation Oncology, University of Ottawa, Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada. wkendal@ottawahospital.on.ca
Abstract
BACKGROUND: Cancer survival is influenced by age, comorbidity, and type of cancer. A population-based study was conducted to compare the interplay between age and mortality for different cancers. METHODS: This study analyzed 784,378 cases, comprising 22 of the commonest SEER cancers diagnosed between 1984 and 1993. Competing hazards and proportional hazard analyses for cancer-specific and comorbid death were performed. RESULTS: Median follow-up was up to 159 months, and the median age of diagnosis was 67 years. Cancer-specific and comorbid deaths accumulated most within the first years of diagnosis. With the more biologically aggressive cancers, cancer deaths invariably exceeded comorbid deaths. For the remaining 70% of cancers, comorbidity remained the dominant mode of death. Deaths attributable to both cancer and comorbidity accumulated mostly after the seventh decade of life. Cancer site had a 3-fold greater effect on overall survival than age at diagnosis and a 30-fold effect with cancer-specific survival; age at diagnosis had a 5-fold greater effect on comorbid deaths than site. CONCLUSIONS: Both the age of the affected individual and the biology of the particular cancer have major influences on cancer survival and mode of death. Cancer is largely a disease of the elderly. Within affected individuals, fatalities attributable to cancer and comorbidity appeared inter-related, with cancer-specific deaths dominating for more lethal cancers and comorbid deaths dominating for the remaining majority. For these reasons, further improvements in overall survival may be best anticipated from better geriatric and general medical management as much as from better cancer management. Copyright (c) 2008 American Cancer Society.
BACKGROUND:Cancer survival is influenced by age, comorbidity, and type of cancer. A population-based study was conducted to compare the interplay between age and mortality for different cancers. METHODS: This study analyzed 784,378 cases, comprising 22 of the commonest SEER cancers diagnosed between 1984 and 1993. Competing hazards and proportional hazard analyses for cancer-specific and comorbid death were performed. RESULTS: Median follow-up was up to 159 months, and the median age of diagnosis was 67 years. Cancer-specific and comorbid deaths accumulated most within the first years of diagnosis. With the more biologically aggressive cancers, cancer deaths invariably exceeded comorbid deaths. For the remaining 70% of cancers, comorbidity remained the dominant mode of death. Deaths attributable to both cancer and comorbidity accumulated mostly after the seventh decade of life. Cancer site had a 3-fold greater effect on overall survival than age at diagnosis and a 30-fold effect with cancer-specific survival; age at diagnosis had a 5-fold greater effect on comorbid deaths than site. CONCLUSIONS: Both the age of the affected individual and the biology of the particular cancer have major influences on cancer survival and mode of death. Cancer is largely a disease of the elderly. Within affected individuals, fatalities attributable to cancer and comorbidity appeared inter-related, with cancer-specific deaths dominating for more lethal cancers and comorbid deaths dominating for the remaining majority. For these reasons, further improvements in overall survival may be best anticipated from better geriatric and general medical management as much as from better cancer management. Copyright (c) 2008 American Cancer Society.
Authors: Ambarina S Faiz; Imran Khan; Michele G Beckman; Paula Bockenstedt; John A Heit; Roshni Kulkarni; Marilyn Manco-Johnson; Stephan Moll; Thomas L Ortel; Claire S Philipp Journal: Thromb Res Date: 2015-07-05 Impact factor: 3.944
Authors: Vanessa B Sheppard; Leigh Anne Faul; George Luta; Jonathan D Clapp; Rachel L Yung; Judy Huei-Yu Wang; Gretchen Kimmick; Claudine Isaacs; Michelle Tallarico; William T Barry; Brandelyn N Pitcher; Clifford Hudis; Eric P Winer; Harvey J Cohen; Hyman B Muss; Arti Hurria; Jeanne S Mandelblatt Journal: J Clin Oncol Date: 2014-06-16 Impact factor: 44.544
Authors: Carol Chen-Scarabelli; Chad McRee; Massoud A Leesar; Fadi G Hage; Tiziano M Scarabelli Journal: J Nucl Cardiol Date: 2016-05-25 Impact factor: 5.952